Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ANDREW LEAVITT

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1952343113
CMS profile
224787
Location
SAN FRANCISCO, CA

General Payments · PY2018–2024

$113,869.97

  • Reported across 80 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$63,507.09

34 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
BioMarin Pharmaceutical Inc. $45,141.58 22
GENZYME CORPORATION $10,498.68 7
PFIZER INC. $7,866.83 5

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $39.77 1
PY2019 $5,435.63 8
PY2020 $9,803.67 3
PY2021 $10,384.56 10
PY2022 $13,042.22 14
PY2023 $11,657.03 10
PY2024 $63,507.09 34

Payment records · PY2024 (34)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
BioMarin Pharmaceutical Inc. $7,397.50 07/01/2024 Travel and Lodging Undisputed 01/23/2026 1127059627 CMS
BioMarin Pharmaceutical Inc. $894.22 09/30/2024 Travel and Lodging Undisputed 01/23/2026 1127059631 CMS
BioMarin Pharmaceutical Inc. $92.40 09/30/2024 Food and Beverage Undisputed 01/23/2026 1127059641 CMS
BioMarin Pharmaceutical Inc. $71.85 09/30/2024 Food and Beverage Undisputed 01/23/2026 1127059677 CMS
BioMarin Pharmaceutical Inc. $35.00 11/14/2024 Travel and Lodging Undisputed 01/23/2026 1127057521 CMS
BioMarin Pharmaceutical Inc. $13.09 11/14/2024 Food and Beverage Undisputed 01/23/2026 1127058543 CMS
BioMarin Pharmaceutical Inc. $3,800.00 11/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127058773 CMS
BioMarin Pharmaceutical Inc. $18.48 11/14/2024 Food and Beverage Undisputed 01/23/2026 1127059211 CMS
BioMarin Pharmaceutical Inc. $49.41 11/14/2024 Travel and Lodging Undisputed 01/23/2026 1127059223 CMS
BioMarin Pharmaceutical Inc. $70.66 11/14/2024 Travel and Lodging Undisputed 01/23/2026 1127059243 CMS
BioMarin Pharmaceutical Inc. $59.99 11/14/2024 Travel and Lodging Undisputed 01/23/2026 1127059247 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057657 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057659 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057661 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057663 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057671 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057673 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057675 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057677 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057679 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057681 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057689 CMS
GENZYME CORPORATION $322.51 11/15/2024 Food and Beverage Undisputed 01/23/2026 1139703131 CMS
GENZYME CORPORATION $44.13 11/15/2024 Food and Beverage Undisputed 01/23/2026 1139703133 CMS
GENZYME CORPORATION $169.86 11/15/2024 Travel and Lodging Undisputed 01/23/2026 1139703135 CMS
GENZYME CORPORATION $359.04 11/15/2024 Travel and Lodging Undisputed 01/23/2026 1139703137 CMS
GENZYME CORPORATION $346.98 11/15/2024 Travel and Lodging Undisputed 01/23/2026 1139703139 CMS
GENZYME CORPORATION $56.16 11/15/2024 Travel and Lodging Undisputed 01/23/2026 1139703141 CMS
GENZYME CORPORATION $9,200.00 11/15/2024 Consulting Fee Undisputed 01/23/2026 1139703143 CMS
PFIZER INC. $2,000.00 03/06/2024 Consulting Fee Undisputed 01/23/2026 1131627975 CMS
PFIZER INC. $720.00 09/10/2024 Consulting Fee Undisputed 01/23/2026 1131908641 CMS
PFIZER INC. $2,880.00 10/15/2024 Consulting Fee Undisputed 01/23/2026 1132040533 CMS
PFIZER INC. $106.83 12/06/2024 Food and Beverage Undisputed 01/23/2026 1131593314 CMS
PFIZER INC. $2,160.00 12/31/2024 Consulting Fee Undisputed 01/23/2026 1131231024 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.